Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02503774 · ClinicalTrials.gov registry record · Phase 1
MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 192
- Enrollment target
NCT02503774 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 192 participants.
The verdict
NCT02503774, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 192 participants
- Enrollment target
Study Summary
The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination with MEDI4736 in Adult Participants with Select Advanced Solid Tumors
Interventions
- DRUG Durvalumab
- DRUG Oleclumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2015-07-24 |
| Est. Completion | 2023-03-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02503774
The ClinicalTrials.gov registry entry for NCT02503774 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Durvalumab is the first listed.
NCT02503774 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02503774 about?
NCT02503774 is a clinical study titled "MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.". The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination with MEDI4736 in Adult Participants with Select Advanced Solid Tumors
What is the current status of trial NCT02503774?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 192 participants. The study started on 2015-07-24. Estimated completion is 2023-03-07.
What interventions are being tested in trial NCT02503774?
The interventions under investigation include: Durvalumab (DRUG), Oleclumab (DRUG).
Who is sponsoring clinical trial NCT02503774?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.